Home Lipid metabolism in overweight/obese children vs. normal weight children in a north-eastern region of Spain
Article Open Access

Lipid metabolism in overweight/obese children vs. normal weight children in a north-eastern region of Spain

  • José Cuenca Alcocel ORCID logo , Lorena Villalba-Heredia , Inés Martínez Redondo , Alba Gallego Royo , José A. Casajús , José M. Arbonés-Mainar and Pilar Calmarza ORCID logo EMAIL logo
Published/Copyright: February 18, 2025

Abstract

Objectives

Obesity and overweight have increased in children and adolescents in Europe in the recent years, accounting for a major global public health problem. The objective of this study was the early detection of metabolic abnormalities in overweight/obese children (8–12 years old) that may ultimately induce impaired glucose metabolism and/or cardiovascular diseases.

Methods

Lipid metabolism and metabolic control parameters were measured and monitored in a group of 61 male and female children with overweight/obesity and a group of 45 healthy, normal weight children, comparing the results obtained. Ages ranged from 8 to 12 years.

Results

Higher levels of triglycerides and insulin and lower levels of high-density lipoprotein (HDL) cholesterol and apolipoprotein A1 were observed in overweight/obese children, as compared to normal weight children. Overweight/obese children exhibited higher apolipoprotein B/apolipoprotein A1 ratio, triglyceride-glucose ratio and HOMA index and a lower low-density lipoprotein (LDL) cholesterol/apolipoprotein B ratio.

Conclusions

Obesity at an early age (8–12 years) negatively affects lipid parameters. Hence, overweight/obese children presented a more atherogenic lipid profile, manifested as higher concentrations of remnant particles and small dense LDL particles, higher insulin resistance and a higher risk for developing diabetes mellitus type 2 and cardiovascular disease, as compared to normal weight children.

Introduction

Obesity and overweight in childhood and/or adolescence have increased in Europe in the recent years [1], accounting for a major global public health problem.

According to the International Obesity Task Force (IOTF) criteria [2], obesity and overweight are defined as a body mass index (BMI) exceeding the cut-offs established by Cole et al. for the equivalent of BMI 30 kg/m2 and 25 kg/m2, respectively.

Obesity is influenced by genetic and environmental factors [3]. Moreover, diet and physical activity play a major role in growth and body weight regulation. A poor diet added to sendentarism, among other factors, may result in child obesity and early atherosclerotic plaque formation. In this setting, subjects may develop even at a young age glucose metabolism disorder such as diabetes mellitus type 2 (DM2), lipid abnormalities or cardiovascular disease (CVD) [4]. Overweight/obesity contribute to the development of the so-called “metabolic syndrome” (MS) in adults and children [5]. MS may induce conditions such as non-alcoholic fatty liver disease, hypertension, coronary heart diseases and musculoskeletal problems. Additionally, overweight/obesity is a risk factor for the development of some types of cancer, poor school performance and mental disorders.

According to the 2019 ALADINO [6] and other studies [7], 8], the prevalence of child obesity/overweight in Spain has remained stable in the recent years; however, it is around 20 % in 6- to 12-year-old children. Interestingly, Spain is the second country with the highest prevalence of child overweight/obesity in Europe [9]. Considering the distribution of child overweight/obesity by sex, overweight is more prevalent among female children, whereas obesity has a higher prevalence among male children.

A variety of population-based studies [10] reveal that the prevalence of dyslipidemia in overweight and obese children and adolescents ranges from 20 % to more than 40 %, respectively. In contrast, only 8–20 % of normal weight children and adolescents have dyslipidemia [11].

The studies assessing dyslipidemia in obese/overweight children in our population are limited, and only a few examine metabolic and hormonal parameters. Of note, some of these studies unveiled an influence of obesity on the concentration of some hormones, including growth hormone, insulin [12], 13], leptin and intact parathyroid hormone (iPTH).

The purpose of this study was to determine a set of basic lipid parameters in obese/overweight children aged 8–12 years in a north-eastern region of Spain. The parameters studied included apolipoproteins A1 and B, lipoprotein (a) and metabolic parameters (insulin, insulin resistance). Results were compared to those obtained for age-matched normal weight children.

Materials and methods

A comparative, observational study involving a group of overweight/obese and a group of normal weight children was performed in Zaragoza, Aragon, Spain. The overweight/obese group was composed of 61 male and female overweight/obese children, as established using the cut-offs defined by Cole et al. [2]. The cohort was extracted from the Exergames study, carried out at the University of Zaragoza and registered to clinicaltrials.gov (ID code NCT04418713). This study was approved by the Ethics Committee of the Regional Government of Aragon (Certificate No. 11/2018, CEICA, Zaragoza, Spain). The purpose of the Active Videogames (Videojuegos Activos after its original title) study, also known as “Exergames” [14], was conducted to examine the effects of an Active Videogaming and Multi-component Exercise program for prepubertal male and female children with overweight/obesity. The normal weight group was composed of 59 girls and boys with normal weight undergoing minor surgery (cryptorchidism, phimosis, trauma, among others). After a review of medical records, patients with confirmed disease and/or overweight/obesity established according to the International Obesity Task Force (IOTF) criteria [2] were excluded.

The final normal weight sample was composed of 45 children.

The two groups included 8 to 12 year-old children living in the autonomous community of Aragon who had not experienced the onset of puberty or menarche in girls (Tanner stages I and II). Children receiving some treatment or who had diseases that may influence study parameters (metabolic or chronic diseases, acute infection, anorexia nervosa) were excluded. Figure 1 displays the subject selection flowchart.

Figure 1: 
Selection of normal weight and overweight/obese children.
Figure 1:

Selection of normal weight and overweight/obese children.

Parents received information about the study to be carry out and all signed the patient informed consent. Then, a short questionnaire was administered to collect epidemiological and clinical data. Anthropometric data included weight, height and body mass index (BMI). Physical examination and a fasting blood test were performed to determine the study parameters and evaluate lipid metabolism and metabolic profile in the study participants.

Blood samples were collected into serum-separator tubes, early in the morning after 8 h overnight fasting. The following basic lipid parameters were determined in serum: total cholesterol (TC), HDL cholesterol (HDL-C) and triglycerides (TG) in an AU 5800 Autoanalyzer (Beckmann Coulter Miami, FL, USA); LDL cholesterol (LDL-C) using the Friedewald formula; apolipoprotein A1 (Apo A1), apolipoprotein B (Apo B) and lipoprotein(a) (lp(a)) in an Immage Autoanalyzer (Beckmann Coulter Miami, FL, USA) by immunonephelometry; and Insulin in a Cobas e411 analyzer (Roche Diagnostics, Spain).

Additionally, Apo A1/Apo B, TG/HDL-C and LDL-C/Apo B ratios were calculated. The triglyceride-glucose index (TyG) was estimated using the following formula: Ln (triglycerides (mg/dL) × blood glucose (mg/dL)/2); the number of remnant particles was estimated using the formula: Total cholesterol – HDL-C – LDL-C; insulin resistance index (HOMA) using the formula: insulin (μU/mL) × blood glucose (mmol/L)/22.5; and quantitative insulin sensitivity check index (QUICKI) using the formula: 1/(log insulin (µU/mL) + log glucose (mg/dL)). Statistical analyses were performed using IBM SPSS Statistics version 26.0.

Firstly, the Lilliefors-corrected Kolmogorov-Smirnov (KSL) test was used to examine the distribution of quantitative anthropometric and biochemical variables. Parametric variables (KSL, p>0.05) were presented as means and standard deviation, whereas non-parametric variables (KSL, p0.05) were expressed as medians and interquartile ranges.

Normally-distributed anthropometric and biochemical variables were compared using Student’s t-test when variances in the two groups were homogeneous or Welck test when variances were non-homogeneous. Differences in non-parametric variables were examined using Mann Whitney U test.

A similar statistical analysis was performed using the tests described above to determine the suitability of the two study groups in terms of age, size and BMI, assessing their comparability in relation to these parameters.

To examine the influence of sex on overweight/obese and normal-weight children, each group was further divided into two sex-based subgroups. As a result, we obtained a subgroup of 34 overweight/obese male children and another subgroup of 27 overweight/obese female children. The normal-weight children group was divided into a subgroup of 29 male children and a subgroup of 16 female children. The tests mentioned above were used to assess significant sex-based differences between the two subgroups in the parameters and indices studied.

The overweight/obese group was also divided into a subgroup of overweight children and another subgroup of obese children by using the IOTF cut-offs. The resulting two subgroups included 40 obese and 21 overweight children, respectively. These subgroups were compared to assess significant differences between both subgroups in the parameters and indices studied.

The correlation between biochemical parameters and BMI, age, and sex was examined. The overweight/obese group was separated from the normal weight group to assess potential correlations with age and sex. The KSL test was first performed in the whole sample to assess the normality of variables. Pearson’s correlation coefficient was used when the variable followed a normal distribution, while Spearman’s correlation coefficient was applied when the distribution was non-normal. In the case of dichotomous variables (as in the case of sex), Kendall Tau-b test was performed. A p-value≤0.05 was established to identify statistical significance.

Results

Table 1 contains the anthropometric data for the overweight/obese group and the normal weight group. No statistically significant differences were observed in terms of age between groups. The proportion of girls and boys was also similar in the two groups (55.7 % of boys in the overweight/obese group vs. 64.4 % in the normal weight group, p=0.367).

Table 1:

Anthropometric data in normal weight and overweight/obese children.

Overweight/obesity (n=61, 34 males and 27 females)d Normal weight (n=45, 29 males and 16 females)d Statistical significance (test) Levene’s test p-value
Total Limits Normality tests Total Limits Normality testc
Age, years 10.1 ± 0.9a (8.4–12.2) 0.200 10.1 ± 1.1a (8.4–12.0) 0.200 0.912 (Welch) 0.014
Weight, kg 55.4 (40.6–70.2)b (33.4–89.1) 0.034 32.3 ± 5.4a (22.0–42.0) 0.200 <0.001 (Mann-Whitney U test)
Height, cm 145 ± 8a (129–161) 0.200 138 ± 9a (119–155) 0.200 <0.001 (Student’s t-test) 0.521
BMI 25.9 ± 3.3a (20.1–36.0) 0.200 17.1 ± 2.4b (13.7–19.9) 0.023 <0.001 (Mann-Whitney U test)

Median Limits Median Limits

Weight Z-score 2.55 (0.63–7.25) −0.56 (−1.75–0.50)
Height Z-score 0.99 (−1.15–3.49) −0.31 (−2.77–2.09)
BMI

Z-score
2.80 (0.80–6.31) −0.62 (−1.65–0.34)
  1. aMean±standard deviation; bmedian (Q1-Q3); cLillefors-corrected Kolmogorov-Smirnov test; dcomparison of the sex distribution in the two groups by Pearson χ2 test (p=0.367).

Weight, height and BMI were statistically higher in the overweight/obese group (p<0.001), as compared to the normal weight group.

Laboratory results and statistical test results are shown in Tables 2 and 3.

Table 2:

Distribution and comparative study of lipid parameters and insulin concentration of overweight/obese children vs. normal weight children.

Lipid parameters Overweight/obese Normal weight Statistical significance (test)d Levene’s test p-value
Value Normality testsc Value Normality testsc
Total cholesterol, mg/dL 167.1 ± 32.6 (158.8–175.5)a 0.200 174.0 ± 24.6 (166.6–181.4)a 0.200 0.215 (Welch) 0.017
LDL cholesterol, mg/dL 98.7 ± 27.3 (91.8–105.7)a 0.194 100.2 ± 18.5 (94.6–105.7)a 0.073 0.747 (Welch) 0.003
Triglycerides, mg/dL 73.0 (61.5–98.5)b <0.001 56.0 (45.5–69.9)b 0.004 <0.001 (Mann-Whitney U test)
HDL cholesterol, mg/dL 51.1 ± 9.6 (48.7–53.6)a 0.200 61.6 ± 13.8 (57.4–65.7)a 0.200 <0.001 (Welch) 0.012
Non-HDL cholesterol, mg/dL 116 ± 31 (107–124)a 0.171 112 ± 19 (107–118)a 0.175 0.473 (Welch) 0.001
Apo A1, mg/dL 148.1 ± 18.7 (143.3–152.9)a 0.182 172.6 ± 30.8 (163.3–181.8)a 0.200 <0.001 (Welch) 0.005
Apo B, mg/dL 81.5 ± 23.3 (75.5–87.4)a 0.200 76.6 ± 15.3 (72.0–81.2)a 0.180 0.195 (Welch) 0.002
Lipoprotein(a), mg/dL 14.5 (5.37–39.60)b <0.001 10.7 (6.42–54.80)b <0.001 0.924 (Mann-Whitney U test)
Insulin, μUI/mL 11.83 (8.95–17.15)b <0.001 6.60 ± 2.71 (5.78–7.43)a 0.200 <0.001 (Mann-Whitney U test)
  1. aMean±standard deviation (95%CI); bmedian (Q1–Q3); cLillefors-corrected Kolmogorov-Smirnov; dvalues in bold indicate statistically significant differences between groups for a 95 % confidence level. Apo A1, apolipoprotein A1; Apo B, apolipoprotein B.

Table 3:

Distribution and comparison of lipid indices and insulin resistance in overweight/obese children vs. normal weight children.

Ratios and index Overweight/obese children Normal weight children Statistical significance (test)d Levene’s p-value
Value Normality testsc Value Normality testsc
Apo B/Apo A1 ratio 0.56 ± 0.19 (0.51–0.61)a 0.099 0.46 ± 0.11 (0.43–0.49)a 0.200 0.001 (Welch) 0.008
TG/HDL cholesterol ratio 1.44 (1.14–2.05)b <0.001 0.88 (1.41–0.66)b 0.001 <0.001 (Mann-Whitney U test)
LDL cholesterol/Apo B index 1.23 ± 0.18 (1.18–1.27)a 0.188 1.32 ± 0.14 (1.28–1.36)a 0.068 0.004 (Student’s t-test) 0.215
T&G indices 8.15 ± 0.45 (8.03–8.26)a 0.200 7.73 ± 0.11 (7.63–7.84)a 0.200 <0.001 (Student’s t-test) 0.053
HOMA index 2.64 (1.86–3.81)b <0.001 1.40 ± 0.61 (1.20–1.61)a 0.200 <0.001 (Mann-Whithey U test)
QUICKI index 0.33 ± 0.03 (0.32–0.34)a 0.200 0.37 (0.35–0.39)b 0.035 <0.001 (Mann-Whitney U test)
Remnant particles, mg/dL 14 (12–19.5)b <0.001 11 (9–14)b <0.001 <0.001 (Mann-Whitney U test)
  1. aMean ± standard deviation (95%CI); bmedian (Q1–Q3); cLillefors-corrected Kolmogorov-Smirnov test; dvalues in bold indicate parameters with statistically significant differences between the two groups for a 95 % confidence level. TG, triglycerides; Apo A1, apolipoprotein A1; Apo B, apolipoprotein B; T&G, triglycerides-glucose.

The group of children with overweight/obesity showed significantly higher TG and significantly lower HDL-C concentrations, as compared to children with normal weight (p<0.001, in the two cases).

Remnant particle concentration was also statistically higher in the overweight/obese group (p<0.001).

The normal weight group exhibited higher levels of Apo A1, as compared to the overweight/obese group (p<0.001). In contrast, higher Apo B concentrations were observed in the overweight/obese group, although differences were not statistically significant (p=0.195). The LDL-C/Apo B ratio (p=0.004) was higher, whereas the TyG index and Apo B/Apo A1 ratio were lower in the normal weight group (p<0.001).

Statistically significant differences were also observed in insulin concentrations, which were higher in the overweight/obese group, as compared to the normal weight group. The HOMA and TyG indices were higher and the QUICKI index was lower in the overweight/obese group (p<0.001, in the two cases).

Percentiles p5, p10, p25, p50, p75, p90 and p95 were calculated for the parameters, ratios and indices with statistically significant differences between the two study groups (Figure 2).

Figure 2: 
Percentiles for lipid and hormonal parameters in normal weight children and overweight/obese children. (A) Triglycerides, (B) HDL cholesterol, (C) Apo A1, (D) insulin, (E) remnant particles, (F) LDL-C/Apo B ratio, (G) TyG index, (H) HOMA index. LDL-C, LDL cholesterol; Apo A1, apolipoprotein A1; Apo B, apolipoprotein B; TyG, triglycerides-glucose.
Figure 2:

Percentiles for lipid and hormonal parameters in normal weight children and overweight/obese children. (A) Triglycerides, (B) HDL cholesterol, (C) Apo A1, (D) insulin, (E) remnant particles, (F) LDL-C/Apo B ratio, (G) TyG index, (H) HOMA index. LDL-C, LDL cholesterol; Apo A1, apolipoprotein A1; Apo B, apolipoprotein B; TyG, triglycerides-glucose.

Considering the sex-based overweight/obese and normal weight subgroups, no statistically significant differences were found in any of the study parameters or ratios. In relation to normal weight subgroups, sex-based differences were only observed in the TyG index (males: 7.66 ± 0.33; females: 7.88 ± 0.27; p=0.041 (Student’s t-test)).

No significant differences were found between children with overweight subgroup and children with obesity subgroup in any of the parameters and ratios studied. A negative correlation was observed between BMI and Apo A1 (r=−0.460; p<0.001) and between BMI and HDL-C (r=−0.433; p<0.001). Additionally, BMI was positively correlated with TG (r=0.396; p<0.001) and insulin (r=0.683; p<0.001). In the normal weight group, there was a positive correlation between age and insulin (r=0.332; p=0.027) and between age and lipoprotein (a) (r=0.349; p=0.019). No significant correlation was observed between sex and the parameters studied.

A negative correlation was found between BMI and LDL-C/ApoB ratio (r=−0.238; p=0.014) and between BMI and QUICKI index (r=−0.677; p<0.001); BMI was positively correlated with ApoB/ApoA1 (r=0.277; p=0.004); TG/HDL-C (r=0.461; p<0.001); TyG (r=0.467; p<0.001); HOMA (r=0.677; p<0.001) and remnant particles (r=0.397; p<0.001).

Only in the normal weight group, age was positively correlated with HOMA (r=0.325; p=0.050) and TyG (r=0.450; p=0.005) and negatively correlated with the QUICKI index (r=−0.370; p=0.024). TyG (r=0.274; p=0.044) showed a positive correlation with female sex, only in normal weight group.

Discussion

Overweight/obese children exhibited a clearly more atherogenic lipid profile than normal weight children. Thus, overweight/obese children have significantly higher levels of TG and lower levels of HDL-C and Apo A1, as compared to normal weight children. These results are consistent with previous studies [15], 16] reporting higher TG and lower HDL-C and Apo A1 concentrations in overweight/obese children. Nielsen et al. [17] documented higher levels of LDL-C, non-HDL-C and TC in male overweight/obese children, as compared to normal weight children. In contrast, no statistically significant differences were observed in these parameters in our study. Consistently with the study by Falaschett et al. [18], BMI was negatively correlated with Apo A1 and HDL. In addition, Apo B concentration was also higher in the overweight group, although differences did not reach significance in our study.

Apart from basic lipid parameters, triglyceride-rich lipoproteins and their metabolites play a major role in the residual risk of CVD. The reason is that these lipoproteins are highly atherogenic, due to their ability to penetrate and be retained in arterial walls, their high cholesterol content and their capacity to produce foam cells. These particles, known as remnant particles, which include chylomicrons, very-low density lipoproteins (VLDL) and intermediate-density lipoprotein (IDL) remnants are associated with the development of atherosclerotic cardiovascular disease [19], 20].

The group of overweight/obese children exhibited higher concentrations of remnant particles, as compared to normal weight group, which is consistent with the results obtained by Slyper et al. [21]. This finding suggests that overweight/obese faces an increased risk for developing atherosclerotic cardiovascular disease.

In relation to Apo A1 and Apo B concentrations, a meta-analysis conducted in 2020, including four papers and a total of 7,974 children and adolescents, revealed that the normal weight group had a 8.13 mg/dL higher mean Apo A1 concentration, compared with the 24.4 mg/dL higher mean Apo A1 concentration in the normal weight group, found in our study. In that study, significant differences were reported in Apo B concentrations between the two groups [22].

As mentioned above, TG/HDL-C and Apo B/Apo A1 ratios were higher in overweight/obese children, whereas the LDL-C/Apo B ratio was lower in the same group.

The Apo B/Apo A1 ratio is considered a major predictor of heart disease in adult obese patients [23]. Moreover, a number of studies in pediatric population report a positive correlation between this ratio and obesity, and an association of this ratio with a higher risk for cardiovascular disease [24], 25]. These results are in agreement with our study, which revealed that overweight/obese children presented a higher Apo B/Apo A1 ratio. Consequently, determination of this ratio can be useful for the early identification of obese children at a higher risk for developing CVD and atherosclerosis.

The LDL-C/Apo B ratio indirectly determines the number of small dense LDL, which are more atherogenic than other forms of LDL particles [26], 27]. A 1.2 ratio has been established to be equivalent to a size of 25.5 nm of LDL particles. It is also the cut-off for establishing a pattern of small dense LDL particles, provided when values of this quotient are equal to or below 1.2 [28]. The value of the LDL-C/Apo B ratio in predicting cardiovascular events with atherosclerotic disease [29] and its correlation with MS [30] has been widely demonstrated in adults. However, there is still insufficient data on its usefulness in the pediatric population. According to the results of our study, overweight/obese children have higher levels of small dense LDL particles and a more atherogenic pattern. Around 50 % of children in this group present a pattern of small dense LDL particles vs. around 25 % in the normal weight group. In a study in adult population, Xiao et al. [31] reported that patients who died from cardiovascular disease had a LDL-C/ApoB ratio <1.2, which was also lower than that of patients who did not die from cardiovascular events. Further studies are needed to assess the predictive value of this ratio in the pediatric population.

In relation to the TG/HDL-C ratio, there is evidence of a role in predicting insulin resistance (IR) and MS in overweight/obese children [32], [33], [34]. In our study, this ratio was found to be higher in overweight/obese children, which represents a higher risk for developing IR in this group. This ratio, along with the HOMA and QUICKI indices can be useful for the early identification of overweight/obese children with a higher IR and the associated higher risk for developing DM2.

Likewise, insulin, glucose concentrations and HOMA and TyG indices were higher in the overweight/obese group, whereas normal weight exhibited a higher QUICKI index.

The HOMA index is an estimation of IR from glucose and fasting insulin [35]. Higher HOMA values are associated with a higher IR [36]. Therefore, the overweight/obese children in our study had higher IR than normal weight children. Considering the cut-offs established for MS-associated IR, a meta-analysis conducted in 2019 [37] revealed that these cut-offs ranged from 2.30 to 3.54 for children and adolescents. According to the percentiles established for HOMA in our study, only 10 % of normal weight children would have IR vs. 50 % of overweight/obese children. In a similar study, Mastroeni et al. [38] also documented higher insulin concentrations and a higher HOMA index in overweight/obese children.

The QUICKI index can also be used to estimate IR. However, its correlation with the gold-standard method (hyperinsulinemic-euglycemic clamp) is slightly poorer than the one of the HOMA index [39]. In our study, overweight/obese children showed lower QUICKI values than normal weight children. These results are consistent with those obtained for the HOMA index, where overweight/obese children had higher IR. Sapunar et al. [40] also reported higher HOMA and lower QUICKI values in overweight/obese children, as compared to normal weight children.

The overweight/obese group also showed higher TyG indices. Like HOMA and QUICKI, the TyG index correlates with the development of IR [41], thereby having a role in assessing the risk for MS [42]. Different TyG cut-offs have been established for diverse populations to predict insulin resistance, based on the HOMA index. Dikaiakau et al. established a cut-off of 7.91 for predicting IR. Based on this cut-off, near 75 % of overweight/obese children in our study could have IR vs. 25 % of normal weight children. In our study, we have also found that children with a higher BMI had a more atherogenic profile and higher IR than normal weight children. Regarding age and sex, normal weight children had slightly higher HOMA and TyG index and a slightly lower QUICKI index as they grew older. The correlation of these parameters with BMI is more intense than with age. A slightly significant correlation was also found between the TyG index and sex, with female children showing slightly higher values than males. These results are in agreement with previous studies revealing an increase in the HOMA index and a decrease in the QUICKI index as children grow [35], 43].

The small sample size is a limitation of this study. However, this study is based on a well-characterized cohort of children at prepubertal age, which is a rarely studied population. This study could be extended to separate overweight from obese children, assess the influence of age and sex, and investigate other more sensitive lipid parameters to establish metabolic and cardiovascular risk in these children.

In conclusion, the group of overweight/obese children with ages from 8 to 12 years exhibited a more atherogenic lipid profile, higher concentrations of remnant and small dense LDL particles – being all very atherogenic – and higher insulin resistance, as compared to normal weight children. This difference involves a higher risk for overweight/obese children to develop DM2 and CVD.


Corresponding author: Pilar Calmarza, Clinical Biochemistry Unit, Miguel Servet University Hospital, Zaragoza, Spain; and Member of the SEQCML Research Groups on Oxidative Stress and Lipoproteins and Vascular Diseases, Research Project Center for Networked Biomedical Research on Cardiovascular Diseases (CIBERCV), University of Zaragoza, Aragon Health Research Institute (IIS Aragón), Zaragoza, Spain, E-mail:

  1. Research ethics: This study complies with all national regulations, institutional policies and ethical principles of the Declaration of Helsinki, and was approved by the Research Ethics Committee of the Autonomous Community of Aragon (CEICA).

  2. Informed consent: Informed consent was obtained from all individuals included in this study, or their legal guardians or wards.

  3. Author contributions: All authors have accepted responsibility for the entire content of this manuscript and approved its submission.

  4. Use of Large Language Models, AI and Machine Learning Tools: None declared.

  5. Conflict of interest: The authors state no conflict of interest.

  6. Research funding: None declared.

  7. Data availability: The raw data can be obtained on request from the corresponding author.

  8. Article Note: The original article can be found here: https://doi.org/10.1515/almed-2024-0113.

References

1. Blundell, JE, Baker, JL, Boyland, E, Blaak, E, Charzewska, J, de Henauw, S, et al.. Variations in the prevalence of obesity among European countries, and a consideration of possible causes. Obes Facts 2017;10:25–37. https://doi.org/10.1159/000455952.Search in Google Scholar PubMed PubMed Central

2. Cole, TJ, Lobstein, T. Extended international (IOTF) body mass index cut-offs for thinness, overweight and obesity. Pediatr Obes 2012;7:284–94. https://doi.org/10.1111/j.2047-6310.2012.00064.x.Search in Google Scholar PubMed

3. Lanigan, J, Barber, S, Singhal, A. Prevention of obesity in preschool children. Proc Nutr Soc 2010;69:204–10. https://doi.org/10.1017/S0029665110000029.Search in Google Scholar PubMed

4. Lavie, CJ, Milani, Rv., Ventura, HO. Obesity and cardiovascular disease. J Am Coll Cardiol 2009;53:1925–32. https://doi.org/10.1016/j.jacc.2008.12.068.Search in Google Scholar PubMed

5. Cook, S, Weitzman, M, Auinger, P, Nguyen, M, Dietz, WH. Prevalence of a metabolic syndrome phenotype in adolescents findings from the third national health and nutrition examination survey, 1988-1994. Arch Pediatr Adolesc Med 2003;157:821–7. https://doi.org/10.1001/archpedi.157.8.821.Search in Google Scholar PubMed

6. AESAN. Estudio ALDINO 2019; 2020. https://www.aesan.gob.es/AECOSAN/web/nutricion/detalle/aladino_2019.htm [Accessed 13 Jul 2024].Search in Google Scholar

7. de Bont, J, Bennett, M, León-Muñoz, LM, Duarte-Salles, T. Prevalencia e incidencia de sobrepeso y obesidad en 2,5 millones de niños y adolescentes en Spain. Rev Esp Cardiol 2022;75:300–7. https://doi.org/10.1016/j.recesp.2021.06.030.Search in Google Scholar

8. de Ruiter, I, Olmedo-Requena, R, Sánchez-Cruz, JJ, Jiménez-Moleón, JJ. Tendencia de la obesidad infantil y el bajo peso por año de nacimiento y edad en Spain, 1983-2011. Rev Esp Cardiol 2017;70:646–55. https://doi.org/10.1016/j.recesp.2016.11.038.Search in Google Scholar

9. Spinelli, A, Buoncristiano, M, Kovacs, VA, Yngve, A, Spiroski, I, Obreja, G, et al.. Prevalence of severe obesity among primary school children in 21 European countries. Obes Facts 2019;12:244–58. https://doi.org/10.1159/000500436.Search in Google Scholar PubMed PubMed Central

10. Brzeziński, M, Metelska, P, Myśliwiec, M, Szlagatys-Sidorkiewicz, A. Lipid disorders in children living with overweight and obesity-large cohort study from Poland. Lipids Health Dis 2020;19:1–9. https://doi.org/10.1186/s12944-020-01218-6.Search in Google Scholar PubMed PubMed Central

11. Dathan-Stumpf, A, Vogel, M, Hiemisch, A, Thiery, J, Burkhardt, R, Kratzsch, J, et al.. Pediatric reference data of serum lipids and prevalence of dyslipidemia: results from a population-based cohort in Germany. Clin Biochem 2016;49:740–9. https://doi.org/10.1016/j.clinbiochem.2016.02.010.Search in Google Scholar PubMed

12. Shalitin, S, Kiess, W. Putative effects of obesity on linear growth and puberty. Horm Res Paediatr 2017;88:101–10. https://doi.org/10.1159/000455968.Search in Google Scholar PubMed

13. Marcovecchio, ML, Chiarelli, F. Obesity and growth during childhood and puberty. World Rev Nutr Diet 2013;106:135–41. https://doi.org/10.1159/000342545.Search in Google Scholar PubMed

14. Comeras-Chueca, C, Villalba-Heredia, L, Perez-Lasierra, JL, Lozano-Berges, G, Matute-Llorente, A, Vicente-Rodriguez, G, et al.. Effect of an active video game intervention combined with multicomponent Exercise for cardiorespiratory fitness in children with overweight and obesity: randomized controlled trial. JMIR Serious Games 2022;10:1–14. https://doi.org/10.2196/33782.Search in Google Scholar PubMed PubMed Central

15. Jaksic, M, Martinovic, M, Gligorovic-Barhanovic, N, Antunovic, T, Nedovic-Vukovic, M. Relationship between insulin-like growth factor-1, insulin resistance and metabolic profile with pre-obesity and obesity in children. J Pediatr Endocrinol Metab 2021;34:301–9. https://doi.org/10.1515/jpem-2020-0447.Search in Google Scholar PubMed

16. Martin, M, Gaete, L, Tetzlaff, W, Ferraro, F, Lozano Chiappe, E, Botta, EE, et al.. Vascular inflammation and impaired reverse cholesterol transport and lipid metabolism in obese children and adolescents. Nutr Metabol Cardiovasc Dis 2022;32:258–68. https://doi.org/10.1016/j.numecd.2021.09.025.Search in Google Scholar PubMed

17. Nielsen, TRH, Lausten-Thomsen, U, Fonvig, CE, Bøjsøe, C, Pedersen, L, Bratholm, PS, et al.. Dyslipidemia and reference values for fasting plasma lipid concentrations in Danish/North-European White children and adolescents. BMC Pediatr 2017;17:1–11. https://doi.org/10.1186/s12887-017-0868-y.Search in Google Scholar PubMed PubMed Central

18. Falaschetti, E, Hingorani, AD, Jones, A, Charakida, M, Finer, N, Whincup, P, et al.. Adiposity and cardiovascular risk factors in a large contemporary population of pre-pubertal children. Eur Heart J 2010;31:3063–72. https://10.1093/eurheartj/ehq355.10.1093/eurheartj/ehq355Search in Google Scholar PubMed PubMed Central

19. Tada, H, Nohara, A, Inazu, A, Mabuchi, H, Kawashiri, Maki. Remnant lipoproteins and atherosclerotic cardiovascular disease. Clin Chim Acta 2019;490:1–5. https://doi.org/10.1016/j.cca.2018.12.014.Search in Google Scholar PubMed

20. Krauss, RM, King, SM. Remnant lipoprotein particles and cardiovascular disease risk. Best Pract Res Clin Endocrinol Metab 2023;37:1–8. https://doi.org/10.1016/j.beem.2022.101682.Search in Google Scholar PubMed

21. Slyper, AH, Rosenberg, H, Kabra, A, Weiss, MJ, Blech, B, Gensler, S, et al.. Early atherogenesis and visceral fat in obese adolescents. Int J Obes 2014;38:954–8. https://doi.org/10.1038/ijo.2014.11.Search in Google Scholar PubMed

22. Jesus, GDS, Costa, PRF, Oliveira, LPM, Queiroz, VAO, Cunha, CM, Pereira, EM. Body adiposity and apolipoproteins in children and adolescents: a meta-analysis of prospective studies. Arq Bras Cardiol 2020;115:163–71. https://doi.org/10.36660/abc.20190331.Search in Google Scholar PubMed PubMed Central

23. Lu, M, Lu, Q, Zhang, Y, Tian, G. ApoB/apoA1 is an effective predictor of coronary heart disease risk in overweight and obesity. J Biomed Res 2011;25:266–73. https://doi.org/10.1016/S1674-8301(11)60036-5.Search in Google Scholar PubMed PubMed Central

24. Castro, APP, Hermsdorff, HHM, Milagres, LC, Albuquerque, FMde, Filgueiras, Mde S, Rocha, NP, et al.. Increased ApoB/ApoA1 ratio is associated with excess weight, body adiposity, and altered lipid profile in children. J Pediatr 2019;95:238–46. https://doi.org/10.1016/j.jped.2017.12.008.Search in Google Scholar PubMed

25. Ojanen, X, Cheng, R, Törmäkangas, T, Rappaport, N, Wilmanski, T, Wu, N, et al.. Towards early risk biomarkers: serum metabolic signature in childhood predicts cardio-metabolic risk in adulthood. EBioMedicine 2021;72:1–10. https://doi.org/10.1016/j.ebiom.2021.103611.Search in Google Scholar PubMed PubMed Central

26. Tani, S, Yagi, T, Atsumi, W, Kawauchi, K, Matsuo, R, Hirayama, A. Relation between low-density lipoprotein cholesterol/apolipoprotein B ratio and triglyceride-rich lipoproteins in patients with coronary artery disease and type 2 diabetes mellitus: a cross-sectional study. Cardiovasc Diabetol 2017;16:123. https://doi.org/10.1186/s12933-017-0606-7.Search in Google Scholar PubMed PubMed Central

27. Hirano, T, Ito, Y, Yoshino, G. Measurement of small dense low-density lipoprotein particles. J Atherosclerosis Thromb 2005;12:67–72. https://doi.org/10.5551/jat.12.67.Search in Google Scholar PubMed

28. Kaneva, AM, Potolitsyna, NN, Bojko, ER. Usefulness of the LDL-C/apoB ratio in the overall evaluation of atherogenicity of lipid profile. Arch Physiol Biochem 2017;123:16–22. https://doi.org/10.1080/13813455.2016.1195411.Search in Google Scholar PubMed

29. Drexel, H, Larcher, B, Mader, A, Vonbank, A, Heinzle, CF, Moser, B, et al.. The LDL-C/ApoB ratio predicts major cardiovascular events in patients with established atherosclerotic cardiovascular disease. Atherosclerosis 2021;329:44–9. https://doi.org/10.1016/j.atherosclerosis.2021.05.010.Search in Google Scholar PubMed

30. Kwon, CH, Kim, BJ, Kim, BS, Kang, JH. Low-density lipoprotein cholesterol to apolipoprotein B ratio is independently associated with metabolic syndrome in Korean men. Metabolism 2011;60:1136–41. https://doi.org/10.1016/j.metabol.2010.12.007.Search in Google Scholar PubMed

31. Xiao, L, Zhang, K, Wang, F, Wang, M, Huang, Q, Wei, C, et al.. The LDL-C/ApoB ratio predicts cardiovascular and all-cause mortality in the general population. Lipids Health Dis 2023;22:1–12. https://doi.org/10.1186/s12944-023-01869-1.Search in Google Scholar PubMed PubMed Central

32. Nur Zati Iwani, AK, Jalaludin, MY, Wan, M, Zin, RM, Fuziah, MZ, Hong, JYH, et al.. TG : HDL-C ratio is a good marker to identify children affected by obesity with increased cardiometabolic risk and insulin resistance. Internet J Endocrinol 2019;2019:1–9. https://doi.org/10.1155/2019/8586167.Search in Google Scholar PubMed PubMed Central

33. Iwani, NAKZ, Jalaludin, MY, Zin, RMWM, Fuziah, MZ, Hong, JYH, Abqariyah, Y, et al.. Triglyceride to HDL-C ratio is associated with insulin resistance in overweight and obese children. Sci Rep 2017:1–7. https://doi.org/10.1038/srep40055.Search in Google Scholar PubMed PubMed Central

34. Krawczyk, M, Rumińska, M, Witkowska-Sędek, E, Majcher, A, Pyrżak, B. Usefulness of the Triglycerides to High-Density Lipoprotein Cholesterol ratio (TG/HDL-C) in prediction of metabolic syndrome in Polish obese children and adolescents. Acta Biochim Pol 2018;65:605–11. https://doi.org/10.18388/abp.2018_2649.Search in Google Scholar PubMed

35. García, CB, García Lacalle, C, Jiménez Lobo, C, González Vergaz, A, Calvo Rey, C, Alcázar Villar, MJ, et al.. Índice HOMA y QUICKI, insulina y péptido C en niños sanos. Puntos de corte de riesgo cardiovascular. Pediatr 2007;66:481–90. https://doi.org/10.1157/13102513.Search in Google Scholar PubMed

36. Shashaj, B, Luciano, R, Contoli, B, Morino, GS, Spreghini, MR, Rustico, C, et al.. Reference ranges of HOMA-IR in normal-weight and obese young Caucasians. Acta Diabetol 2016;53:251–60. https://doi.org/10.1007/s00592-015-0782-4.Search in Google Scholar PubMed

37. Arellano-Ruiz, P, García-Hermoso, A, Cavero-Redondo, I, Pozuelo-Carrascosa, D, Martínez-Vizcaíno, V, Solera-Martinez, M. Homeostasis Model Assessment cut-off points related to metabolic syndrome in children and adolescents: a systematic review and meta-analysis. Eur J Pediatr 2019;178:1813–22. https://doi.org/10.1007/s00431-019-03464-y.Search in Google Scholar PubMed

38. Mastroeni, SS, Mastroeni, MF, Gonçalves Mde, C, Debortoli, G, da Silva, NN, Bernal, RT, et al.. Cardiometabolic risk markers of normal weight and excess body weight in Brazilian adolescents. Appl Physiol Nutr Metabol 2016;41:659–65. https://doi.org/10.1139/apnm-2015-0632.Search in Google Scholar PubMed

39. Henderson, M, Rabasa-Lhoret, R, Bastard, JP, Chiasson, JL, Baillargeon, JP, Hanley, JA, et al.. Measuring insulin sensitivity in youth: how do the different indices compare with the gold-standard method? Diabetes Metab 2011;37:72–8. https://doi.org/10.1016/j.diabet.2010.06.008.Search in Google Scholar PubMed

40. Sapunar, J, Aguilar-Farías, N, Navarro, J, Araneda, G, Chandia-Poblete, D, Manríquez, V, et al.. High prevalence of overweight, obesity, insulin resistance and metabolic syndrome in rural children and adolescents. Rev Med Chile 2018;146:978–86. https://doi.org/10.4067/s0034-98872018000900978.Search in Google Scholar PubMed

41. Dikaiakou, E, Vlachopapadopoulou, EA, Paschou, SA, Athanasouli, F, Panagiotopoulos, Ι, Kafetzi, M, et al.. Τriglycerides-glucose (TyG) index is a sensitive marker of insulin resistance in Greek children and adolescents. Endocrine 2020;70:58–64. https://doi.org/10.1007/s12020-020-02374-6.Search in Google Scholar PubMed

42. Dundar, C, Terzi, O, Arslan, HN. Comparison of the ability of HOMA-IR, VAI, and TyG indexes to predict metabolic syndrome in children with obesity: a cross-sectional study. BMC Pediatr 2023;23:1–9. https://doi.org/10.1186/s12887-023-03892-8.Search in Google Scholar PubMed PubMed Central

43. Kim, S, Song, K, Lee, M, Suh, J, Chae, HW, Kim, H-S, et al.. Trends in HOMA-IR values among South Korean adolescents from 2007–2010 to 2019–2020: a sex-age-and weight status-specific analysis. Int J Obes 2023;47:865–72. https://doi.org/10.1038/s41366-023-01340-2.Search in Google Scholar PubMed PubMed Central

Received: 2024-07-20
Accepted: 2024-11-24
Published Online: 2025-02-18

© 2025 the author(s), published by De Gruyter, Berlin/Boston

This work is licensed under the Creative Commons Attribution 4.0 International License.

Articles in the same Issue

  1. Frontmatter
  2. Editorial
  3. Lights and shadows of artificial intelligence in laboratory medicine
  4. Luces y sombras de la inteligencia artificial en la medicina de laboratorio
  5. Review / Artículo de Revisión
  6. Fundamentals of lipoprotein(a) request and quantification in the clinical laboratory
  7. Aspectos fundamentales en la solicitud y determinación de la lipoproteína(a) en el laboratorio clínico
  8. Original Article / Artículo Original
  9. Evaluating seven bioinformatics platforms for tertiary analysis of genomic data from whole exome sequencing in a pilot group of patients
  10. Evaluación de siete programas bioinformáticos para el análisis terciario de datos genómicos generados a partir de la secuenciación del exoma completo en un grupo piloto de pacientes
  11. Parameters of glycemic variability in continuous glucose monitoring as predictors of diabetes: a prospective evaluation in a non-diabetic general population
  12. Parámetros de variabilidad glucémica de la monitorización continua de glucosa como predictores de diabetes: evaluación prospectiva en una población general sin diabetes
  13. Reference intervals of hematological parameters in the Chilean adult population and the Mapuche ethnic group
  14. Intervalos de referencia de parámetros hematológicos en población chilena adulta y en la etnia mapuche
  15. Lipid metabolism in overweight/obese children vs. normal weight children in a north-eastern region of Spain
  16. Estudio del metabolismo lipídico en niños aragoneses con sobrepeso/obesidad vs. niños normopeso
  17. Short Communication / Comunicación Breve
  18. Evaluating the research parameters available on the Sysmex® XN-series hematology analyzers as markers of dysplasia in peripheral blood
  19. Valoración de los parámetros de investigación de los analizadores hematológicos de la serie XN (Sysmex®) como marcadores de displasia en sangre perifèrica
  20. Evaluation of an alternative centrifugation protocol for reducing total turnaround time
  21. Evaluación de un protocolo de centrifugación alternativo que permita reducir el tiempo de respuesta total
  22. Case Report / Caso Clínico
  23. Jordans’ anomaly in Chanarin-Dorfman syndrome
  24. Anomalía de Jordans en síndrome de Chanarin-Dorfman
  25. Letter to the Editor / Carta al Editor
  26. Considerations about the use of glucometers in glucose tolerance tests
  27. Consideraciones acerca del uso de glucómetros durante la prueba de tolerancia oral a la glucosa
  28. Reply to: “Considerations about the use of glucometers for testing glucose tolerance”
  29. Respuesta a la carta al editor: “Consideraciones acerca del uso de glucómetros durante la prueba de tolerancia oral a la glucosa” (https://doi.org/10.1515/almed-2024-0108)
Downloaded on 9.5.2025 from https://www.degruyterbrill.com/document/doi/10.1515/almed-2025-0015/html
Scroll to top button